14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AKTS vs DTIL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Precision BioSciences, Inc. (DTIL) is the stronger overall head-to-head candidate over AKTS (AKTS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKTS carries a Unified Composite Score of 30.6/100 (SELL) at $16.49 (N/M Forward P/E, N/A operating margin), whereas DTIL carries 41.0/100 (SELL) at $7.36 (11.8x Forward P/E, -80.3% operating margin).
Defensive Composite Rating Caution: Although DTIL compares more favorably head-to-head, both AKTS (30.6/100 SELL) and DTIL (41.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: AKTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.1); meanwhile DTIL is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKTS vs DTIL. Trailing 12-month operating profitability (AKTS N/A vs DTIL -80.3%) and valuation multiples (AKTS N/M vs DTIL 11.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $306.9M market capitalization and -80.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AKTS vs DTIL Key Questions & Quantitative Answers
As of Nov 16, 2026, Precision BioSciences, Inc. (DTIL) is the stronger overall head-to-head candidate over AKTS (AKTS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKTS carries a Unified Composite Score of 30.6/100 (SELL) at $16.49 (N/M Forward P/E, N/A operating margin), whereas DTIL carries 41.0/100 (SELL) at $7.36 (11.8x Forward P/E, -80.3% operating margin). Defensive Composite Rating Caution: Although DTIL compares more favorably head-to-head, both AKTS (30.6/100 SELL) and DTIL (41.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: AKTS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.1); meanwhile DTIL is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DTIL leads the Growth & Scale pillar: AKTS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with DTIL at +37272.4% YoY revenue growth and +0.0% YoY earnings growth on $45M TTM revenue (100.0% gross margin, -80.3% operating margin). On trailing 12-month operating scale, AKTS generates N/A in USD-normalized revenue versus $45M for DTIL. In operating R&D and SG&A reinvestment, AKTS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DTIL.
DTIL screens cheaper on headline valuation multiples. AKTS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas DTIL trades at 11.8x Forward P/E, 32.2x Trailing P/E, N/M PEG, and 5.6x EV/Revenue (-116.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKTS (N/A ROE) versus DTIL (-115.3% ROE) capital efficiency.
In options market volatility and institutional positioning, AKTS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.36β · 66% Vol realized risk). By comparison, DTIL carries 112.8% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.31β · 126% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.